DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy

DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy

June 18, 2018 Agreement with Glooko Provides Broad Access of Insulin Pump Therapy Optimization to Physicians, Patients and Payers PETAH TIKVA, Israel, June 18, 2018 /PRNewswire/ — DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that the U.S Food and Drug Administration

Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer

Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer

June 18, 2018 – Encore investor webcast presentation June 23, 2018 – BOULDER, Colo., June 18, 2018 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated safety and efficacy results, including overall survival (OS) data, from the safety lead-in

Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in the Management of Patients with Metastatic Breast Cancer

Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in the Management of Patients with Metastatic Breast Cancer

June 18, 2018 Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept’s Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive SAN DIEGO, June 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC),

Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

June 18, 2018 HACKENSACK, N.J., June 18, 2018 /PRNewswire/ — Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation,

Migraine Abortion Phase 3 Trial (TEAM study) with Cefaly® ACUTE Medical Device is Progressing Quickly

Migraine Abortion Phase 3 Trial (TEAM study) with Cefaly® ACUTE Medical Device is Progressing Quickly

June 18, 2018 The Cefaly® ACUTE medical device, recently cleared by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine, is the subject of a large phase 3 clinical trial in the United States that is progressing rapidly. Previous pilot

Elekta Unity, World’s First High-Field MR-Linac, Receives CE Mark

Elekta Unity, World’s First High-Field MR-Linac, Receives CE Mark

une 18, 2018 New radiation therapy system will now be implemented clinically in Europe, ushering in a transformation in precisionand personalized cancer treatment Elekta (EKTA-B.ST) earlier today announced (14:15 CET) that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark, clearing the technology for

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

June 18, 2018 sANDA approval is for manufacturing of Atovaquone and Proguanil Hydrochloride Tablets, 250 MG/100 MG AND 62.5 MG/25 MG at Monroe facility PARAMUS, N.J., June 18, 2018 /PRNewswire/ — Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S.

Hyundai Hope On Wheels Presents Phoenix Children’s Hospital With $100,000 Hyundai Impact Award To Support Pediatric Cancer Research

Hyundai Hope On Wheels Presents Phoenix Children’s Hospital With $100,000 Hyundai Impact Award To Support Pediatric Cancer Research

June 18, 2018 The organization will surpass $145 million in lifetime funding celebrating its 20th Year in ‘Saving Lives and Creating Hope’ to End Childhood Cancer PHOENIX, June 18, 2018 /PRNewswire/ — Hyundai Hope On Wheels® 501(c)(3) non-profit organization, celebrates its 20th year in

Mylan Launches Generic Angiomax® Injection

Mylan Launches Generic Angiomax® Injection

June 18, 2018 – Bivalirudin for Injection is an anticoagulant intended for use with aspirin – HERTFORDSHIRE, England and PITTSBURGH, June 18, 2018 /PRNewswire/ — Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic

European Hematology Association: A New Anti-CD22 CAR-T Immunotherapy Saved Life of Children With Leukemia

European Hematology Association: A New Anti-CD22 CAR-T Immunotherapy Saved Life of Children With Leukemia

June 16, 2018 B acute lymphoblastic leukemia (B-ALL) is a fatal blood cell tumor that is usually treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HCT), and CD19-CAR-T cell therapy has been successful in treating refractory or relapsed (r/r)

European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It’s as Simple as A-D-C

European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It’s as Simple as A-D-C

June 16, 2018 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Unfortunately, 40% of patients will relapse after or not respond to initial treatment resulting in poor outcomes especially if stem cell transplant is not

European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström’s Macroglobulinemia

European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström’s Macroglobulinemia

June 16, 2018 Waldenström’s Macroglobulinemia (WM) is a rare type of blood cancer. Since WM is rare, it is difficult to conduct large clinical studies and determine a standard treatment for the disease. Rituximab, a therapy used to treat other

European Hematology Association: Overall Survival Benefit of Obinutuzumab Over Rituximab When Combined With Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Comorbidities

European Hematology Association: Overall Survival Benefit of Obinutuzumab Over Rituximab When Combined With Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Comorbidities

June 15, 2018 Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that is able to attack chronic lymphocytic leukemia (CLL) by binding and destroying malignant CLL cells. Rituximab is a non-glycoengineered type I anti-CD20 monoclonal antibody that also binds

Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity

Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity

June 15, 2018 – Overall Response Rate of 83% – – Durable Ongoing Responses Up to 22 Months – – All Patients Evaluable on Measures of Mast Cell Burden Showed Marked Improvements,with 58% Showing Complete Resolution of Bone Marrow Mast

JAK Inhibitors Associated with Aggressive Lymphoma

JAK Inhibitors Associated with Aggressive Lymphoma

June 15, 2018 Study suggests screening patients to prevent second malignancy WASHINGTON, June 15, 2018 /PRNewswire/ — Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.

Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018

Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018

PRINCETON, N.J., June 14, 2018 /PRNewswire/ — Taiho Oncology, Inc. and Servier today announced that clinical data for LONSURF® (trifluridine and tipiracil, TAS-102) are being presented at the ESMO 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain, June 20 to 23. In addition, Taiho

Diabetes Technology Society Article on Blood Glucose Monitor System (BGMS) Surveillance Program Is Published in Diabetes Care

Diabetes Technology Society Article on Blood Glucose Monitor System (BGMS) Surveillance Program Is Published in Diabetes Care

June 14, 2018 Patients will benefit by payers, including Medicare, considering the implementation of safeguards to ensure patients have access to BGMSs that meet accuracy guidelines BURLINGAME, Calif., June 14, 2018 /PRNewswire/ — Diabetes Technology Society (DTS) announces the Diabetes Care publication of

Pioneer of MR Image-Guided Radiotherapy, Washington University, Begins First Clinical Treatments with its Second ViewRay MRIdian System

Pioneer of MR Image-Guided Radiotherapy, Washington University, Begins First Clinical Treatments with its Second ViewRay MRIdian System

June 13, 2018 Next Generation Cancer Therapy Enables Delivery of Higher, Potentially More Effective Radiation Dose Regimens CLEVELAND, June 13, 2018 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis,

EpiVax Oncology Completes a $1.2M Bridge Financing

EpiVax Oncology Completes a $1.2M Bridge Financing

NEW YORK and PROVIDENCE, R.I., June 12, 2018 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC. EpiVax Oncology, Inc. (EO)

Gene Therapy R&D and Revenue Forecasts 2018-2028 – Visiongain Report

Gene Therapy R&D and Revenue Forecasts 2018-2028 – Visiongain Report

LONDON, June 12, 2018 /PRNewswire/ — Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Rare Diseases, Ophthalmologic Conditions, Other Diseases, Approved Gene therapies, R&D Pipeline Analysis, Gene Therapy Regulations by Region and Leading Players The gene therapy market is projected to grow at

Statement from FDA Commissioner Scott Gottlieb, M.D., on new agency efforts to advance the patient voice in medical product development and FDA regulatory decision-making

Statement from FDA Commissioner Scott Gottlieb, M.D., on new agency efforts to advance the patient voice in medical product development and FDA regulatory decision-making

SILVER SPRING, Md., June 12, 2018 /PRNewswire-USNewswire/ — Over the past decade, advances in our understanding of the basic biology of serious and life-threatening diseases has led to the development and FDA approval of targeted treatments for patients with a

Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts

Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts

June 12, 2018 – Will accelerate discovery of next-generation immunodementia therapeutics that go beyond A-beta and tau by targeting immune mechanisms identified by human genetics – Represents significant 10-year investment by Eisai for drug discovery through novel integration of human

PCMA Statement on HELP Committee Hearing on President’s Blueprint to Lower Drug Prices

PCMA Statement on HELP Committee Hearing on President’s Blueprint to Lower Drug Prices

WASHINGTON, June 12, 2018 /PRNewswire-USNewswire/ — The Pharmaceutical Care Management Association (PCMA)released the following statement on the Health, Education, Labor and Pensions Committee hearing, “The Cost of Prescription Drugs: Examining the President’s Blueprint ‘American Patients First’ to Lower Drug Prices:” “We share the Administration’s

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics–Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics–Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya

June 12, 2018 Growth of the IL-17 inhibitors and Tremfya has been at the expense of the established TNF inhibitors and Janssen’s own Stelara. EXTON, Pa., June 12, 2018 /PRNewswire/ — Spherix Global Insights’ second quarter update of RealTime Dynamix™: Psoriasis (US) reveals significant changes

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

DARMSTADT, Germany, June 11, 2018 /PRNewswire/ — Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in MET-positive, advanced hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function These data provide further evidence of tepotinib activity in patients with MET-positive advanced cancers Given